objeCtives: To evaluate costs associated with the use of dexmedetomidine in comparison with standard care sedation (propofol or midazolam) in Spain in intensive care unit (ICU) patients through a cost-minimisation and a budget impact analyses. Methods: The population consisted of ICU ventilated patients requiring a mild to moderate level of sedation. Time spent at ICU was estimated based on two head-to-head published clinical trials (PRODEX, MIDEX) comparing the two sedative strategies. The time horizon was inpatient stay at ICU considering three periods: mechanical ventilation, non-mechanical ventilation and off ventilator. The analysis considered the Spanish National Health System (NHS) perspective and only included ICU stay and sedative costs, which were obtained from Spanish sources (2017 prices). We adapted a previously built model, which was based on published data: average body weight 72.0 kg, current 24h cost of dexmedetomidine (1 amp 2 ml: € 18), midazolam (10 amp 1 ml: € 1.60), propofol (1 vial 100 ml: € 6.90) and 1 day ICU stay cost (€ 1,497.85) . Results: The estimated mean costs per ICU patient discharge were € 18,653 with standard care and € 18,236 with dexmedetomidine. Savings per patient treated were € 417 (€ 655 versus midazolam and € 180 versus propofol). A 30% change of sedated patients at ICU from standard care (50% midazolam, 50% propofol) to dexmedetomidine in a cohort of 1000 patients/year would result in yearly savings of at least € 417,220 for the Spanish NHS and 294 ICU free days (that allow to treat 62 additional patients/year). ConClusions: Dexmedetomidine reduces the duration of mechanical ventilation and is a cost-saving alternative to propofol and midazolam at the ICU setting in Spain.
PSY35 thE EffEctivEnESS anD coSt-EffEctivEnESS of DiffErEnt mEthoDS of rEcruiting PatiEntS to a Pain StuDY
Wade A, Crawford GM Patients Direct, Glasgow, UK objeCtives: To compare the effectiveness and cost-effectiveness of different methods in recruiting patients with acute soft-tissue injuries to a pain study. Methods: We used a number of different methods to recruit patients with acute soft-tissue injuries to a pain study. The success rate of these methods in recruiting the 182 patients who entered the study and the base cost of each method (not including internal resource costs) differed dramatically. Here we have examined the effectiveness and cost-effectiveness of the different recruitment methods to determine the best options for generating suitable patient populations for similar future studies. Results: In total, 762 participants were screened by telephone, but only 182 patients were admitted to the study. Of the 182 patients who participated, 100 (55%) were recruited through Facebook advertising at a total cost of £2,001; 27 (15%) were recruited by TV advertising at an approximate cost of £14,640; 22 (12%) had responded to posters/leaflets costing approximately £1,000; and 3 patients (1.5%) were recruited by press advertising at a cost of £480. There were no costs associated with recruiting 21 (11.5%) patients by word-of-mouth and 9 (5%) patients by unknown methods. Of the methods that required a financial investment, the most cost-effective means of recruiting patients who actually entered the study was Facebook advertising (£20 per patient). Using posters/leaflets for recruitment was also good value, costing approximately £45 per patient. In contrast, press and TV advertising were expensive, costing approximately £160 and £542 per patient, respectively. ConClusions: Facebook advertising was particularly effective in finding individuals with suitable soft-tissue injuries for a pain study, and 55% of our study participants were recruited by this method. Facebook advertising was also a cost-effective method of recruitment (£20 per patient) and was 8-fold and 27-fold more cost-effective than using press and TV advertising, respectively. objeCtives: Surgery poses a risk condition for haemophilia patients. Prophylactic strategy is required to avoid increasing of bleeds. This study aimed to estimate the cost of activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa) prophylaxis therapy in haemophilia patients with inhibitors undergoing surgery. Methods: A decision analytic model was developed to estimate the cost for the Spanish National Health system of providing hemostatic coverage with bypassing agents for haemophilia patients with inhibitor undergoing surgery. Age split (children and adults) and correspondent average weights related to haemophiliac population derived from literature. Annual number of surgeries (0.33/patient) was obtained from local data. Dental extraction and major surgeries were assumed only to happen in adult population (≥ 14 years) whilst minor surgery occurrence was split into children 22.80% (< 14 years) and adults 77.20%. Drug costs (€ ,2017) considered official ex-factory prices with 7.5% of mandatory deduction (0.74€ /IU [aPCC], 0.54€ /IU [rFVIIa]) and the recommended dosing stated on Summaries of Products Characteristics and duration regimens according to each or third line treatment in addition to O-MTX and CSA generated cost savings of £300-£311 million (£9,395-£9,728 per patient) over 5 years. Including SC-MTX also delayed biologic treatment by 13.9 months. ConClusions: SC-MTX is a viable alternative to conventional systemic treatments for moderate-to-severe psoriasis in the UK. Its inclusion in the treatment pathway is likely to be of considerable economic benefit.
PSY36

BYPaSSing agEntS ProPhYlaxiS in PatiEntS With haEmoPhilia anD inhiBitorS unDErgoing SurgErY: a DEciSion analYSiS in SPain
PSY31 a litEraturE analYSiS of coSt StuDiES on cancEr
Dolek B Bristol Myers Squibb Inc Turkey, Istanbul, Turkey objeCtives: Pharmacoeconomic studies present and measure the use of costeffectiveness analysis mainly at country basis, in the literature. In Turkey, the ratio of total health expenditures to GDP is 5.4%. Around 159,000 people are annually diagnosed with cancer and almost 69,000 of them died every year. Direct treatment cost of cancer is app. € 1 billion annually, means that cancer share of all health expenditures would be 3%. This study aims to review literature regarding cost studies conducted in Turkey in the field of cancer through the PubMed, ISPOR data base and ULAKBIM and to draw attention to the low number of studies. Methods: Three databases (PubMed, ISPOR and ULAKBIM) were searched up to June 15, 2017 using the keywords of cost, cancer, and Turkey. Results: There were only 48 publications/presentations, of which 27/9/12 from PubMed/ISPOR/ULAKBIM. Only 12 studies (3/PubMed, 5/ISPOR and 4 ULKABIM) could be included in the analysis as they contained costs for Turkish population. Of these studies, 3 were on lung cancer, 1 on colon cancer, 2 was on cancer pain, 3 was on renal cancer ,2 were on renal and lung cancers and 1 on farmakogenetic issues in cancer treatment. According to these studies: the total cost of lung cancer per-patient was approximately € 10,698±13, 190. The total direct medical cost of lung, breast, hematological, head and neck, colorectal, gastric, gynecological, and prostate cancers ranged between € 1077-4675 (2014). The median total cost per patient was € 912 in non-small cell lung cancer patients and € 908 in small cell lung cancer patients. ConClusions: Although Turkey is a country with 80 million population and has a well-developed health system, such small number of cost studies about cancer; the second cause of all deaths, is an issue that should be addressed.
PSY32 launching comBination thEraPiES in rarE DiSEaSES: iS high coSt BurDEn rEStricting accESS?
Rupasinghe B, Gilbane A, Schlegel CR, Walsh K, Degun R Navigant Consulting, London, UK objeCtives: Upfront combination therapy has been shown to be clinically beneficial in certain patient groups in rare diseases. However, the potentially high economic burden associated with combination therapy in the rare disease space maybe restricting patient access. This research aims to explore innovative pricing and contracting options that have already been implemented in the cancer space which may also be considered within rare diseases with a view to increase patient access to combination therapies whilst minimising cost burden. Methods: Primary research with payers in the UK, France, Germany, Spain and Italy were probed on market dynamics that will affect the pricing of combination therapy in their markets. Potential contracting strategies were evaluated in each market and the feasibility of launching fixed dose combinations in rare diseases were explored. Results: Over the next 5 years, innovative pricing and contracting options are expected to be increasingly adopted in the EU5 markets to reduce the increasing economic burden associated with combination therapy within the rare disease space. Particular value was seen in simple price discounting along with more complex patient outcomes related contracting measures. Fixed dose combinations offering a 5-30% reduction compared to standalone drug prices given in combination was seen as a crucial component to success in all markets. ConClusions: The increasing burden of combination therapy in rare diseases maybe restricting access; this burden maybe eased by the introduction of innovative contracting. Furthermore, the introduction of a fixed dose combination could prove to be successful if priced at a discount in comparison to the cost of standalone drugs given in combination.
PSY33 Economic Evaluation anD BuDgEt imPact analYSiS of ProthromBin comPlEx concEntratE (BEriPlEx®) for trEatmEnt anD ProPhYlaxiS of BlEEDing in PatiEntS trEatED With oral anticoagulantS unDEr PErSPEctivE of hEalth PuBlic inStitutionS in mExico
Maciel-Hernandez H 1 , Paladio-Hernandez J 2 , Salazar-Alvarado B 1 1 CSL Behring Mexico, Mexico, Mexico, 2 Independent Consultant, Mexico, Mexico objeCtives: Most important adverse event associated with the use of oral anticoagulants is bleeding and sometimes it is necessary to reverse anticoagulation. The objective of this study is to compare the costs of using Prothrombin Complex Concentrate (PCC) in comparison to Fresh Frozen Plasma (FFP) in Health Public Institutions in order to identify the cost-saving anti-bleeding treatment. Methods: Since PCC and FFP have the same safety and efficacy profile, a cost-minimization study and budget impact analysis were conducted, by examining the comparison of anti-bleeding treatment in patients with oral anticoagulants (warfarin). Standard of treatment was a 70 Kg patient. Time horizon was considered duration of bleeding episode and there was not applied discount rate. The analysis were presented in 3 scenarios according to International Normalized Index ranges, from 2.0-3.9, 4.0-6.0 and > 6.0. Unitary costs and budget were obtained from Health Public Institutions in 2016. Results: In the first scenario, anti-bleeding treatment cost for PCC was $764 USD and for FFP was $1,369 USD (-$615 USD). In the second scenario treatment cost for PCC was $955 USD and for FFP was the same as in first scenario (-$423 USD). In the third scenario treatment cost for PCC was $1,338 USD and for FFP was $1,838 USD (-$500 USD). The cumulative 5-year cost for 10,000 estimated cases of bleeding per year in patients with INR> 6.0 was for PCC $18.7 USD million and for FFP was $25.7 USD million. The 5-year Budget Impact Analysis showed savings for $7 USD
